Neurocrine Biosciences (NASDAQ:NBIX) Earns “Outperform” Rating from William Blair

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “outperform” rating restated by equities research analysts at William Blair in a report issued on Monday,RTT News reports.

A number of other research firms have also issued reports on NBIX. Royal Bank of Canada dropped their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Raymond James reiterated an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Jefferies Financial Group boosted their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $148.00 price target on shares of Neurocrine Biosciences in a report on Monday. Five investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.00.

Neurocrine Biosciences Trading Up 2.7 %

NASDAQ:NBIX opened at $136.69 on Monday. Neurocrine Biosciences has a 12 month low of $110.95 and a 12 month high of $157.98. The firm has a market cap of $13.84 billion, a P/E ratio of 35.67 and a beta of 0.34. The stock has a 50 day moving average of $122.16 and a two-hundred day moving average of $130.57.

Insider Activity

In related news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC increased its position in shares of Neurocrine Biosciences by 34.0% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,357 shares of the company’s stock worth $875,000 after acquiring an additional 1,613 shares during the period. Envestnet Portfolio Solutions Inc. increased its holdings in Neurocrine Biosciences by 6.6% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 2,710 shares of the company’s stock worth $373,000 after purchasing an additional 168 shares during the period. Pallas Capital Advisors LLC raised its position in Neurocrine Biosciences by 26.4% in the 2nd quarter. Pallas Capital Advisors LLC now owns 3,098 shares of the company’s stock valued at $447,000 after purchasing an additional 647 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Neurocrine Biosciences by 14.7% in the 2nd quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock valued at $99,000 after buying an additional 92 shares during the period. Finally, Fifth Third Wealth Advisors LLC acquired a new position in shares of Neurocrine Biosciences during the second quarter worth about $435,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.